Featured Editorial

  1. From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair 6/1/2026

    Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.

  2. Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking 5/29/2026

    RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.

  3. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.

  4. RNA Manufacturing Foundations: From DNA Templates To In Vitro Transcription (Pt. 1) 5/27/2026

    Cell-free RNA production is reshaping biomanufacturing through modular IVT workflows, advanced capping strategies, and scalable DNA template design.

  5. Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein Research 5/26/2026

    Researchers expanded translational repression assays beyond RNA hairpins, enabling scalable study of linear RNA-protein interactions in living cells.

  6. Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency 5/22/2026

    New research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.

  7. Beyond Guanidine: Scientists Discover A Mysterious Riboswitch Variant With A Different Biological Target 5/22/2026

    Scientists identified a mysterious riboswitch variant that resembles guanidine sensors but likely evolved to detect an entirely different metabolite.

  8. The Cell-Free Revolution: Breaking The Plasmid DNA Bottleneck 5/20/2026

    I was excited to be given the opportunity to sit down with Jodi Barrientos, CEO, Ribbon Bio, to learn more about the current state of the synthetic DNA space. In the following Q&A, Barrientos and I discuss some of the synthetic DNA industry’s biggest goals and the challenges that stand in the way of bringing synthetic plasmids more commonly into the mRNA development paradigm. 

  9. RNA Modification-Mediated Translational Control In Immune Cells 5/20/2026

    Exploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.

  10. Repeating Sanofi's Ballroom Design On Two Continents 5/15/2026

    Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.